Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shivkumar Madki"'
Autor:
Bhavatharini P A, Mahendra Joshi, Archana Kakkar, Shivkumar Madki, Vijay Ivaturi, Girish Chinnaswamy, Shripad Banavali, Vikram Gota
AIMS 6 mercaptopurine (6MP) is the mainstay chemotherapy for acute lymphoblastic leukaemia (ALL) and is conventionally available as 50 mg tablets. This study aimed to evaluate the bioequivalence of a new 6MP Powder for Oral Suspension (PFOS) intended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ec03c03f5716fbc7e000545cb7f444a
https://doi.org/10.22541/au.168347165.51047819/v1
https://doi.org/10.22541/au.168347165.51047819/v1
Autor:
Rukmini Kethireddypally, P.V. Prashanthi, Mammen Chandy, Cartikeya Reddy, Reena Rajsekhar, Alok Srivastava, Auro Viswabandya, Shivkumar Madki, Dhiraj Abhayankar, Biju George, Vikram Mathews, C. Nirmala Raju
Publikováno v:
Blood. 110:4491-4491
Addition of rituximab (375 mg/m2) to CHOP has been shown to improve survival in patients with DLBCL. However there is limited data on the pharmacokinetics (PK) and pharmacodynamics (PD) of this drug in this condition. We have evaluated the PK and PD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a210b6e9630c7316580deaa09b1271f1
https://doi.org/10.1182/blood.v110.11.4491.4491
https://doi.org/10.1182/blood.v110.11.4491.4491
